Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Position Lifted by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 3.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 269,741 shares of the company’s stock after acquiring an additional 9,054 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Organogenesis were worth $755,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. lifted its stake in Organogenesis by 309.3% during the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after purchasing an additional 3,005,450 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Organogenesis during the first quarter worth $1,846,000. Acadian Asset Management LLC lifted its position in shares of Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock worth $8,521,000 after buying an additional 471,741 shares during the last quarter. Wealth Dimensions Group Ltd. boosted its holdings in shares of Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock valued at $1,142,000 after buying an additional 331,840 shares during the period. Finally, GSA Capital Partners LLP boosted its holdings in shares of Organogenesis by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 531,218 shares of the company’s stock valued at $1,509,000 after buying an additional 269,315 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Price Performance

Shares of NASDAQ ORGO opened at $2.83 on Monday. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70. The firm has a market capitalization of $375.18 million, a PE ratio of 70.75 and a beta of 1.62. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42. The business’s fifty day moving average price is $2.80 and its two-hundred day moving average price is $2.75.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). The firm had revenue of $130.23 million during the quarter, compared to analyst estimates of $122.48 million. Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. On average, research analysts expect that Organogenesis Holdings Inc. will post -0.19 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Lake Street Capital assumed coverage on shares of Organogenesis in a report on Friday, June 28th. They issued a “buy” rating and a $5.00 target price on the stock.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.